SPRUCE BIOSCIENCES INC (SPRB) Fundamental Analysis & Valuation

NASDAQ:SPRB • US85209E2081

Current stock price

54.01 USD
+1.65 (+3.15%)
Last:

This SPRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SPRB Profitability Analysis

1.1 Basic Checks

  • In the past year SPRB has reported negative net income.
  • SPRB had a negative operating cash flow in the past year.
  • SPRB had negative earnings in each of the past 5 years.
  • In the past 5 years SPRB always reported negative operating cash flow.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • With a Return On Assets value of -73.49%, SPRB is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • SPRB has a Return On Equity (-91.65%) which is in line with its industry peers.
Industry RankSector Rank
ROA -73.49%
ROE -91.65%
ROIC N/A
ROA(3y)-78.97%
ROA(5y)-64.86%
ROE(3y)-112.77%
ROE(5y)-88.74%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K

1.3 Margins

  • SPRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SPRB Health Analysis

2.1 Basic Checks

  • SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SPRB has more shares outstanding than it did 1 year ago.
  • SPRB has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SPRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K 800K 1M
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -4.86, we must say that SPRB is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -4.86, SPRB is not doing good in the industry: 63.57% of the companies in the same industry are doing better.
  • SPRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.86
ROIC/WACCN/A
WACC9.6%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • SPRB has a Current Ratio of 5.17. This indicates that SPRB is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SPRB (5.17) is comparable to the rest of the industry.
  • SPRB has a Quick Ratio of 5.17. This indicates that SPRB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.17, SPRB is in line with its industry, outperforming 56.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.17
Quick Ratio 5.17
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SPRB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.42% over the past year.
  • SPRB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)44.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.61%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, SPRB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.90% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.82%
EPS Next 2Y33.61%
EPS Next 3Y23.75%
EPS Next 5Y14.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

1

4. SPRB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SPRB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • SPRB's earnings are expected to grow with 23.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.61%
EPS Next 3Y23.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SPRB Dividend Analysis

5.1 Amount

  • No dividends for SPRB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPRB Fundamentals: All Metrics, Ratios and Statistics

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (4/23/2026, 4:22:54 PM)

54.01

+1.65 (+3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-04
Inst Owners67.68%
Inst Owner Change0%
Ins Owners7.2%
Ins Owner Change0.22%
Market Cap73.99M
Revenue(TTM)N/A
Net Income(TTM)-38.97M
Analysts86
Price Target202.22 (274.41%)
Short Float %13.45%
Short Ratio3.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.53%
Min EPS beat(2)-38.48%
Max EPS beat(2)-2.58%
EPS beat(4)1
Avg EPS beat(4)-1.3%
Min EPS beat(4)-46.19%
Max EPS beat(4)82.06%
EPS beat(8)4
Avg EPS beat(8)-15.01%
EPS beat(12)7
Avg EPS beat(12)-4.38%
EPS beat(16)10
Avg EPS beat(16)-1.85%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.65%
PT rev (3m)-13.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)-53.11%
EPS NY rev (3m)-793.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-53.36
EYN/A
EPS(NY)-37.45
Fwd EYN/A
FCF(TTM)-24.33
FCFYN/A
OCF(TTM)-24.33
OCFYN/A
SpS0
BVpS31.03
TBVpS31.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -73.49%
ROE -91.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.97%
ROA(5y)-64.86%
ROE(3y)-112.77%
ROE(5y)-88.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.17
Quick Ratio 5.17
Altman-Z -4.86
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.61%
EPS Next Y29.82%
EPS Next 2Y33.61%
EPS Next 3Y23.75%
EPS Next 5Y14.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.45%
OCF growth 3YN/A
OCF growth 5YN/A

SPRUCE BIOSCIENCES INC / SPRB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SPRUCE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to SPRB.


Can you provide the valuation status for SPRUCE BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to SPRUCE BIOSCIENCES INC (SPRB). This can be considered as Overvalued.


How profitable is SPRUCE BIOSCIENCES INC (SPRB) stock?

SPRUCE BIOSCIENCES INC (SPRB) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for SPRB stock?

The Earnings per Share (EPS) of SPRUCE BIOSCIENCES INC (SPRB) is expected to grow by 29.82% in the next year.